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Abstract The future of medicine lies in early diagnosis and
individually tailored treatments, a concept that has been des-
ignated ‘personalised medicine’ (PM), which aims to deliver
the right treatment to the right patient at the right time. Med-
ical imaging has always been personalised and is funda-
mental to almost all aspects of PM. It is instrumental in
solving clinical differential diagnoses. Imaging procedures
are tailored to the clinical problem and patient character-
istics. Screening for preclinical disease is done with imag-
ing. Stratification based on imaging biomarkers can help iden-
tify individuals suited for preventive intervention. Treatment
decisions are based on the in vivo visualisation of the location
and extent of an abnormality, as well as the loco-regional phys-
iological, biochemical and biological processes using structural
and molecular imaging. Image-guided biopsy provides rel-
evant tissue specimens for genetic/molecular characteri-
sation. In addition, radiogenomics relate imaging bio-
markers to these genetic and molecular features. Fur-
thermore, imaging is essential to patient-tailored therapy
planning, therapy monitoring and follow-up of disease,
as well as targeting non-invasive or minimally invasive
treatments, especially with the rise of theranostics. Ra-
diologists need to be prepared for this new paradigm as
it will mean changes in training, clinical practice and in
research.
Key Points
• Medical imaging is a key component in personalised
medicine
• Personalised prevention will rely on image-based
screening programmes
• Anatomical, functional and molecular imaging bio-
markers affect decisions on the type and intensity of
treatment
• Treatment response assessment with imaging will im-
prove personalised treatment
• Image-based invasive intervention integrates personalised
diagnosis and personalised treatment
Keywords Individualizedmedicine . Theranostics .
Biomarkers . Radiogenomics . Precisionmedicine
Introduction
In 2011, the ESR published its first white paper on per-
sonalised medicine (PM) [1]. The focus of this article was
on the important and essential role of medical imaging in early
diagnosis and individually tailored treatment. The article con-
cluded that medical imaging plays a critical role in all aspects
of PM: prediction, diagnosis and especially treatment. Thus,
for PM to reach its highest potential, medical imaging must
play an integral role. As the developments in PM are rapid, it
is time to update the original white paper and provide a thor-
ough overview of all areas in PM in which imaging plays a
role. Currently, national and European funding agencies as
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well as public-private collaborations support large research
programmes and infrastructures dedicated to PM [2]. It is im-
portant that the benefits and contributions of clinical imaging
and imaging research to PM are acknowledged and supported
in order to fulfil the promises of PM. As PM has already
entered the clinical arena, it is also important that the medical
imaging community is aware of this concept and is prepared
for participating as a relevant partner in PM.
Therefore, the ESR considers it of strategic importance to
describe how medical imaging contributes to PM and to
delineate major obstacles to the full application of imaging
in PM in daily practice. This white paper concludes with
recommendations for the medical imaging field.
Definition
Sequencing of the human genome in 2003 opened the way to
identifying specific genes that are involved in particular dis-
eases and thus supports the identification of genetic variants
that either predispose an individual to a specific disease or
regulate that individual’s sensitivity to a given treatment [3].
The promise of PM lies in the prediction of disease risk, the
choice of the right treatment and the assessment of the treat-
ment response and safety profile based on genomic sequence
data. Thus, many consider PM to be synonymous with geno-
mic medicine (Table 1). However, the European Science
Foundation (ESF) stated that the range of information that
can be used to customise healthcare is far greater than genome
sequence data alone. Their definition of PM is broadly de-
scribed as a customisation of healthcare that accommodates
individual differences as far as possible at all stages in the
process, from prevention, through diagnosis and treatment,
to post-treatment follow-up. In other words, it is about provid-
ing the right treatment to the right patient at the right time [3].
The National Academy of Sciences of the USA prefers the
term “precision medicine” instead of “personalised medicine”
as it does not literally mean the creation of drugs or medical
devices that are unique to a patient, but rather the ability to
classify individuals into subpopulations that differ in their
susceptibility to a particular disease, in the biology and/or
prognosis of those diseases they may develop, or in their re-
sponse to a specific treatment [4].
Genetic differences may determine disease predisposition
and therapeutic response in some diseases. However, most dis-
eases are polygenic in nature and highly influenced by environ-
mental factors including climate, social context and behavioural
factors such as diet and exercise. The final disease manifesta-
tion or phenotype is the result of gene-environment interaction,
and it is expected that differences in the biochemical, biological
and physiological characteristics (e.g., perfusion, flow, metab-
olism, diffusion) of diseased lesions are important factors to be
taken into account when tailoring personalised treatment. For
that reason the ESF stated that “genomics, epigenomics,
proteomics, metabolomics, lipidomics and other ‘omics tech-
nologies, such as analysis of the microbiome, will be required
alongside imaging and physiological monitoring to generate
biological data. All of this information, along with additional
data on environmental exposures and lifestyle, for instance, will
need to be integrated, analysed and interpreted” [3].
PM is not only relevant for diagnosis and treatment of can-
cer, but for most persistent diseases that require aggressive
treatment or treatment with considerable side effects. PM not
only takes into account disease but also patient characteristics as
these may also influence the susceptibility to treatment and side
effects [5]. PM is not a totally new approach. Medical care is
traditionally delivered at a personal level, and clinicians adapt
their therapeutic approach to the individual needs of the patient.
In this unique physician-patient relationship, all relevant aspects
of a human being and its context are taken into account in both
the diagnostic process as well as the subsequent treatment, giv-
en the state-of-the-art knowledge at the time of the physician-
patient interaction. In the past, personal experience has been the
prevailing source of knowledge whilst more recently this
knowledge has been amended, sometimes to a greater extent,
by the collective experience recorded in scientific publications.
This has led to specific guidelines, which are based on diagnos-
tic and treatment outcome in a large number of patients with the
same type of disease. PM as perceived today will take into
account more in-depth diagnostic information from the patient
and its disease for the right treatment allocation.
The promises of PM are better diagnoses, earlier interven-
tions, more efficient drug development, more effective thera-
pies, reduction of side effects of treatment and improved cost
effectiveness. Better diagnosis is based on information on ge-
netic variants, gene expression, and biological and physiolo-
gical description of disease. Earlier intervention is based on
better diagnostic tools to identify individuals with a predispo-
sition for the development of a particular condition and to
monitor interventions that might prevent it, delay its onset or
reduce its impact. More efficient drug development is based
on a better understanding of disease, which could help scien-
tists identify new disease subgroups and their associated mo-
lecular pathways as well as design drugs that target them.
More effective therapies are achieved by selecting the right
patients for treatment and by selecting the type of treatment
(surgery, radiotherapy, chemotherapy and/or targeted therapy)
and the intensity of treatment (the best dosing schedule or
radiation dose for a particular patient). Reduction of side
effects of treatment is achieved by identification of
patients who are at risk for developing side effects, by
reduction of the number of patients that are exposed to
non-effective treatment. Cost-effectiveness is achieved by
pre-selecting patients for treatment or by terminating
inefficient treatments early.
There are multiple areas in which medical imaging has and
will have a major impact in PM (Table 2).
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Personalised diagnosis
Medical imaging intrinsically enables PM. The first step lead-
ing from clinical symptoms and signs to a diagnosis relies on
imaging in a substantial number of diseases. Besides imaging,
laboratory analysis of body fluids such as blood, serum, urine
or stool also play an important role in the diagnostic process.
Imaging has played this role for decades by the assessment of
the location of disease in individual patients and by character-
isation of the structural abnormalities. While classical macro-
scopic imaging provides some of the most important
‘individualised’ information on many diseases—namely their
localisation and extent—its value for determining the specific
aetiology is sometimes limited. Final diagnosis within an ac-
ceptable degree of uncertainty is usually possible based on a
combination of clinical, biochemical (laboratory) and imaging
information. However, pathological diagnosis of lesions de-
tected by imaging is frequently needed.
Recent advances in imaging using specific radiotracers will
provide additional tools for better characterisation of a lesion
at the molecular level. The combination of different functional
and molecular parameters extracted frommultimodality imag-
ing techniques will probably reduce the need for pathological
diagnosis of lesions.
Key examples of personalised diagnosis include:
& Patients with abdominal pain have a clinical evaluation
first and — dependent on the results — additional tests
including imaging are performed, which rule out impor-
tant disease, confirm a clinical diagnosis or narrow a dif-
ferential diagnosis.
& Patients with an acute neurologic deficit are evaluated with
a brain CT and/or MRI to differentiate between ischaemic
stroke, intraparenchymal haemorrhage, subarachnoid
haemorrhage, sinus thrombosis or a rare cause of stroke.
Table 1 Definitions of terms related to personalised medicine
Personalised medicine
• According to Wikipedia, "Personalized medicine is a medical model
that proposes the customization of healthcare using molecular
analysis—with medical decisions, practices, and/or products being
tailored to the individual patient. In this model, diagnostic testing is
often employed for selecting appropriate and optimal therapies based
on the context of a patient’s genetic content. The use of genetic
information has played a major role in certain aspects of personalised
medicine and the term was first coined in the context of genetics,
though it has since broadened to encompass all sorts of
personalization measures" [104]
• The US National Human Genome Research Institute defines
personalised medicine as an emerging practice of medicine that uses
an individual’s genetic profile to guide decisions made in regard to
the prevention, diagnosis and treatment of disease. Knowledge of a
patient’s genetic profile can help doctors select the proper medication
or therapy and administer it using the proper dose or regimen [105]
• The US National Cancer institute describes personalised medicine as
a form of medicine that uses information about a person’s genes,
proteins, and environment to prevent, diagnose, and treat disease. In
cancer, personalised medicine uses specific information about a
person’s tumour to help diagnose, plan treatment, find out how well
treatment is working, or make a prognosis. Also called precision
medicine [106]
• European Science Foundation: Personalised medicine can be broadly
described as a customisation of healthcare that accommodates
individual differences as far as possible at all stages in the process,
from prevention, through diagnosis and treatment, to post-treatment
follow-up [3]
• National Academy of Sciences: Precision medicine refers to the
tailoring of medical treatment to the individual characteristics of each
patient. It does not literally mean the creation of drugs or medical
devices that are unique to a patient, but rather the ability to classify
individuals into subpopulations that differ in their susceptibility to a
particular disease, in the biology and/or prognosis of those diseases
they may develop, or in their response to a specific treatment.
Preventive or therapeutic interventions can then be concentrated on
those who will benefit, sparing expense and side effects for those
who will not. Although the term “personalisedmedicine” is also used
to convey this meaning, that term is sometimes misinterpreted as
implying that unique treatments can be designed for each individual.
For this reason, the Committee thinks that the term “precision
medicine” is preferable to “personalised medicine” [4]
Pharmacogenomics
The study of how a person’s genes affect the way he or she responds to
drugs. Pharmacogenetics is being used to learn ahead of time what
the best drug or the best dose of a drug will be for a person [106]
Genomic medicine
The use of genetic information to improve health outcomes
Stratified medicine
The identification of subgroups of patients with a particular disease
who respond to a particular drug or, alternatively, are at risk of side
effects in response to a certain treatment [3]
Theranostics
The term “theranostics” was coined to define ongoing efforts in clinics
to develop more specific, individualised therapies for various
diseases and to combine diagnostic and therapeutic capabilities into a
single agent [107]
Radiogenomics
Radiogenomics is a relatively recently coined term that describes the
relationship between imaging features of a lesion and the underlying
Table 1 (continued)
genetic/molecular features. It can be helpful for improved
personalised diagnosis, prognosis, and assessment of treatment
response [72]
Companion diagnostics
A companion diagnostic device can be an in-vitro diagnostic device
(IVD) or an imaging tool that provides information that is essential for
the safe and effective use of a corresponding therapeutic product. The
use of an IVD companion diagnostic device with a particular
therapeutic product is stipulated in the instructions for use in the
labelling of both the diagnostic device and the corresponding
therapeutic product as well as in the labelling of any generic
equivalents and biosimilar equivalents of the therapeutic product [108]
Genomic profile
Information about all the genes in an organism, including variations,
gene expression, and theway those genes interact with each other and
with the environment. A genomic profile may be used to discover
why some people get certain diseases while other people do not or
why people respond differently to the same drug [106]
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& Patients with trauma are evaluated with conventional X-
ray or CT scans to rule out or confirm and localise frac-
tures, haemorrhage and contusions.
& Patients with angina pectoris are evaluated for underlying
coronary artery stenosis by coronary angiography or CT
angiography or for underlying myocardial viability by nu-
clear medicine or cardiac MRI.
& The diagnosis of diabetes mellitus or hyperthyroidism is
based on laboratory examinations.
& Patients with symptoms caused by a tumour are biopsied
to evaluate the type and aggressiveness of the lesion.
Diagnoses in these examples are based on clinical evalua-
tion, imaging, laboratory examinations or evaluation of tissue
specimens. Conceptually, in personalised diagnosis a large
group of patients with similar symptoms is subdivided into
smaller groups with a specific diagnosis and subsequent treat-
ment allocation.
Personalised diagnostic procedure
Medical imaging procedures are tailored to the clinical prob-
lem of the patient and to patient characteristics. The main aims
are to perform the right diagnostic procedure for an individual
problem, to optimise the quality of the diagnostic examination
and to reduce the side effects of the diagnostic procedure. All
these aims fit in the concept of PM.
Many radiological organisations provide information
about the indications for imaging and the choice of
modality in their referral or appropriateness criteria [6,
7]. Specific imaging protocols per modality have been
designed to tackle a broad range of clinical problems.
These protocols differ for example in the effective pa-
tient dose, the amount of contrast injected, injection
rate, delay times, image reconstruction algorithms, con-
trast weightings, slice thicknesses and image orientation.
Examples of tailored protocols for a specific clinical prob-
lem are low-dose CT protocols for urinary stone detection [8],
CT angiography for detection of arterial stenosis and MRI for
spinal cord diseases. Examples of optimisation of a diagnostic
procedure based on patient characteristics are contrast media
dosing based upon patient weight [9, 10], scan delay in MR or
CTangiography based on bolus tracking. Examples of patient
characteristics used to reduce side effects of the diagnostic
procedure are measures to avoid the use of ionising radiation
when imaging children and pregnant women [11, 12], to pre-
vent the use of IV contrast media in patients with eGFR<
30 ml/min/1.73 m² [13], and automated tube voltage selection
and tube current modulation in CT based on measured atten-
uation [14, 15].
Imaging in personalised prevention
Many common diseases have a long subclinical history before
they become clinically evident. Biomedical imaging allows
for the non-invasive assessment of in vivo structural and func-
tional changes that may reflect specific pathologies. This
makes it possible to investigate specific pathophysiological
substrates of disease in the pre-symptomatic phase and at the
population level. Screening a clinically healthy population
with imaging to detect and characterise these subclinical ab-
normalities and to treat the individuals at risk might be an
optimal strategy in preventive medicine. Personalised preven-
tion with imaging will result in detection and treatment at the
right time and in stratification of the main group into sub-
groups with low, intermediate and high risk of developing
disease. Each group might have its own treatment regime,
ranging from discharge, regular follow-up at several years,
watchful waiting with an imaging follow-up after several
months, or a medical or surgical intervention.
Screening
Screening can be considered as PM as it can provide treatment
of disease in a timely fashion before the disease has become
Table 2 Imaging and personalised medicine
Diagnosis:
From symptoms to underlying diagnosis with the support of imaging
Diagnostic procedure:
Imaging procedures tailored to the clinical problem and patient
characteristics
Prevention/screening:
Imaging to improve risk stratification or to detect preclinical disease
Selection of the right treatment with imaging information
Imaging to assess the localisation and extent disease
Imaging for functional and biological characterisation of lesions
Image-guided biopsy to get specimens for genetic/molecular
characterisation
Imaging biomarkers to predict response to treatment, recurrence and
survival
Agents that can be used for imaging diagnostics and therapeutic
purposes (theranostics)
Imaging biomarkers associated with genetic/molecular features
(radiogenomics)
Evaluation of treatment response:
Imaging to assess early the effects of treatment in order to adapt
treatment
Imaging in drug discovery and drug trials:
Surrogate imaging biomarkers to evaluate the effect of new
personalised treatment
Personalised treatment:
Image-guided treatment with surgical, radiotherapeutical, minimally or
non-invasive interventional procedures
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clinically manifest with a decreased chance of implementing
curative treatment. Imaging-based screening programmes are
not only performed in healthy subjects. Patients can also enter
an imaging screening programme to detect the progression of
disease or development of cancer in an earlier phase (Table 3).
The objective of these screening programmes is to start treat-
ment earlier than it would be if based on clinical progression.
Well-known examples are the image-based screening
programmes for breast, lung, colorectal and prostate cancer
[16–18]. Some programmes include all subjects within a cer-
tain age range; others identify high-risk categories based on
simple algorithms.
The main problem with the detection of asymptomatic dis-
ease is the potential for overdiagnosis. Overdiagnosis is the
diagnosis of irrelevant diseases or diseases that are sufficiently
stable or indolent that they would not have become clinically
relevant during the subject’s lifetime. Overdiagnosis leads to
unneeded treatment with potentially harmful side effects and
thus causes both economic and emotional burden. The mag-
nitude of overdiagnosis has been recently estimated to be as
much as 25 %–60 % in breast, lung and prostate cancer
screening [19]. Fortunately, imaging not only plays a role in
the detection of subclinical abnormalities, but can also be used
to characterise the lesion as aggressive or indolent. For exam-
ple, the large number of non-specific nodules detected during
lung cancer screening can be addressed by follow-up imaging
to assess the change in the volume of the nodule, thereby
reducing the number of false-positive diagnoses [20]. A com-
plementary molecular imaging technique allows for better
characterisation of incidental findings from screening proce-
dures, such as solitary lung nodules, dense breast lesions and
suspected prostate cancer, thus avoiding unnecessary invasive
procedures and biopsies in patients with negative molecular
scans [21].
Prevention of disease
Currently, prevention of cardiovascular disease and stratifica-
tion of the healthy population are based on the Framingham
risk score or Systematic Coronary Risk Evaluation (SCORE)
score. Based on classical risk factors including age, gender,
systolic blood pressure, hypertension treatment, smoking, to-
tal and HDL cholesterol, an individual is classified as having a
low, intermediate or high risk. High-risk individuals are treat-
ed with intensive medical treatment while low-risk individuals
are helped with lifestyle modifications. The main problem
here is the large intermediate-risk group. Extensive research
has been performed to better stratify patients within the inter-
mediate risk group. As imaging is able to detect presymptom-
atic atherosclerotic disease, it is logical to hypothesise that
imaging may become the key to identifying people who could
benefit from preventive intervention. Candidate imaging bio-
markers are the CT-derived calcium score from the coronary
arteries [22] or more peripherally located arteries, US-derived
intima-media thickness, US- or MRI-derived pulse wave ve-
locity [23], or MRI-based plaque composition [24]. These
imaging biomarkers can predict later development of disease,
either on their own or by supplementing established risk fac-
tors [22]. The development of such new prevention strategies
requires imaging at the population level. Population imaging
is performed within the context of large population-based,
prospective epidemiological studies. Population imaging
focusses on finding imaging biomarkers that allow early diag-
nosis of preclinical disease and prediction of clinical disease.
Besides imaging, information about the history of the individ-
ual subject, blood and body fluid samples, genetic data and
most importantly follow-up data with regard to the develop-
ment of symptoms and disease are available for correlation.
Imaging in the selection of treatment
Location and extent of disease
Although the question “Where is the disease and what is it?”
may have been clearly answered, a clear decision on the opti-
mal treatment cannot always be made without taking into
consideration additional imaging data. For example, know-
ledge of the extent of a disease—a parameter of the severity
of disease—is crucial for decisions on the choice of treatment.
Table 3 Examples of screening programmes with imaging
Screening programme Image modality Subjects Biomarker
Breast cancer Mammography Females>40 years BIRADS
Breast cancer MRI Females with BRCA1 or BRCA2 Lesion
Lung cancer CT thorax People with an increased risk profile Nodule
Abdominal aortic aneurysm US Males>50 years Maximal diameter
Hepatocellular carcinoma US Patients with hepatitis Lesion
Unruptured cerebral aneurysms DSA, CTA, MRA Patients with small intracerebral aneurysm Diameter (increase)
Meningioma MRI Patients with small meningioma Size (increase)
Ascending aorta CT thorax Patients with Marfan’s disease Diameter (increase)
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The classical example is tumour staging in which the involve-
ment of adjacent tissues, regional lymph nodes and distant
metastasis has an immediate and important impact on prog-
nostic stratification and on the choice of therapeutic options.
Improved staging with the use of imaging might help in
avoiding unnecessary surgical interventions, which increases
the morbidity of disease without a substantial benefit in the
reduction of mortality. On the other hand upstaging can lead to
the choice of more aggressive therapies, whichmay reduce the
recurrence rate [25, 26].
Tumour staging relies strongly on cross-sectional imaging,
with CT and/or MRI information being combined with quan-
titative metabolic information from PETand SPECT imaging.
General consensus criteria and guidelines have been
established based on large clinical studies combining multi-
modality imaging criteria [27–29]. In these guidelines PET/
CT is increasingly used in staging. This technique, which
visualises specific tracer uptake in normal and abnormal tis-
sue, allows for better localisation of cancer in structurally nor-
mal tissue. Moreover, the whole-body approach increases the
sensitivity for distant metastases. The improvement in staging
with PET/CT compared to PET or CT alone is substantial and
has been reported for many cancers and cancers of unknown
primary [30, 31]. Cost-effectiveness of preoperative PET has
been proven with, for example, prevention of unnecessary
surgery in one out of five patients with suspected non-small-
cell lung cancer after the addition of [18F]FDG-PET im-
aging to conventional staging [32]. Recent emergence of
combined PET/MR imaging systems is expected to raise
the potential for combined criteria in better assessment
and tissue characterisation of specific tumour and path-
ological lesions.
Besides oncology, cardiovascular and cerebrovascular dis-
eases are other areas where severity of disease influences treat-
ment decisions. Specific examples are:
& The decision to treat unruptured intracranial aneurysms is
based on the location and maximum diameter of the an-
eurysm [33].
& Abdominal aneurysms larger than 5.5 cm are treated while
smaller aneurysms are monitored during follow-up [34].
& Atherosclerotic stenosis in coronary and peripheral arter-
ies is considered symptomatic and is treated once the di-
ameter stenosis is more than 50 %.
& The benefit of carotid endarterectomy has been proven for
symptomatic stenosis of more than 70%. The carotid end-
arterectomy trials have used catheter angiography as the
modality for the assessment of the severity of stenosis
[35]. US, CTA and MRA have replaced this technique
after extensive validation as the accurate assessment of
the severity of stenosis was crucial in treatment decisions.
It is therefore not surprising that carotid stenosis is one of
the most evaluated imaging biomarkers in radiology.
Tissue biopsy in interventional radiology
Final diagnosis of specific diseases and subsequent treatment
allocation has been based on gross macroscopic, microscopic
and/or immunohistochemical evaluation of tissue specimens.
The best-known example is a tumour for which the most rel-
evant question is the assessment of the malignant nature of the
lesion and the type of malignancy. Collection of tissue sam-
ples for diagnosis can been performed by endoscopy or with a
surgical procedure. US-, CT- or MRI-guided biopsy sampling
is critical and most often represents the least invasive method
to obtain relevant material for the in vitro diagnosis of disease
in many parts of the body. Specific examples include:
& MRI-guided or contrast-enhanced transrectal US-guided
prostate biopsy, which appears to be a useful method for
the detection of prostate cancer in patients with prior neg-
ative biopsy results [36, 37].
& US- and MRI-guided percutaneous breast biopsy, which
has replaced surgical biopsy as the initial method of diag-
nosis for most breast lesions [38].
Tissue sampling is not only performed for a final patholog-
ic diagnosis, but also for the evaluation of disease spread.
Here, the confirmation of potential metastasis through
image-guided tissue sampling may change the type of treat-
ment offered, for example from surgery to radiotherapy and/or
chemotherapy. Specific examples include:
& US-guided core biopsy of suspicious axillary lymph nodes
in patients with breast cancer allows for identification of
metastatic nodes preoperatively [38, 39].
& CT-guided bone biopsy in patients with suspected bone
metastasis supports a final diagnosis [40].
& US-guided biopsy in sub-centimetre neck lymph nodes
improves tumour staging in head and neck cancer [41].
Prognostic and predictive biomarkers
The essence of personalised diagnosis for personalised treat-
ment lies in the use of biomarkers. These can be extracted
from tissue, body fluids or medical imaging. In the selection
of the right treatment, two different types of biomarkers are of
particular importance: prognostic and predictive biomarkers.
Prognostic imaging biomarkers predict the likelihood of dis-
ease progression in the absence of treatment considerations.
Such biomarkers are valuable not only for identifying aggres-
sive disease that requires immediate treatment, but also for
identifying indolent disease that can safely be left alone.
& Pre-treatment tumour volume on PET/CT in breast cancer
patients predicts tumour recurrence during follow-up [42].
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& Baseline lesion glycolysis measured with [18F]FDG-PET
predicts progression-free survival in diffuse large B-cell
lymphoma [43].
Predictive biomarkers indicate the relative sensitivity or
resistance to drug treatment or the success of treatment by
surgery, interventional radiology or radiotherapy.
& CT-derived perfusion parameters in metastatic renal cell
cancer can predict the biological response to
antiangiogenic drugs [44].
& Dynamic contrast-enhanced (DCE) MRI to evaluate the
non-enhancing tumour fraction predicts the response to
chemo-radiotherapy in advanced cervical cancer [45].
Both types of biomarkers are relevant in PM as they influ-
ence the decision for the treatment, type, length and intensity
of treatment. A specific application of a prognostic or predic-
tive biomarker is the monitoring of the response after the first
cycle of treatment (chemotherapy and/or radiotherapy) in or-
der to predict the final response, progression-free survival,
recurrence and overall survival.
& [18F]FDG-PET response after the first cycles of chemo-
therapy predicts the final response as well as progression-
free survival and overall survival [46].
& Diffusion-weighted (DWI) MRI of metastatic ovarian and
peritoneal cancer was not able to predict response, while
an increase in ADC after the first or third of six cycles of
chemotherapy was able to predict tumour response [47].
Multiple prognostic and predictive imaging biomarkers
have been identified. The main challenge for PM is the trans-
lation of this information in patient management pathways
and treatment algorithms.
Molecular imaging
PM implies the identification of the specific genomic and
molecular substrate of alterations leading to disease and “med-
ical treatment tailored not just to symptoms, but to the bio-
chemical profile of an individual’s disease state (gene expres-
sion, proteome, dominant metabolic pathways, etc.)” [48].
This has tremendously changed the evaluation of diseased
tissue specimens: from microscopic and/or immunohisto-
chemical evaluation to gene expression profiling.
Parallel to this development, medical imaging has changed.
Traditionally, medical imaging has been a tool for non-invasive
assessment of anatomy and for detection and localisation of dis-
ease processes. Currently, a wide variety of newmedical imaging
techniques produces important information about physiology,
metabolism, molecular biological processes and functional geno-
mics. Multiple methods have been described for imaging the
temporal and spatial biodistribution of a molecular probe as well
as related biological processes such as cell proliferation, apopto-
sis, angiogenesis, hypoxia, and gene activation and expression.
These newmethods combine the ability to measure and quantify
biological processes with the ability to localise the measured
entities onto a high-resolution anatomical and functional image
[49]. In the future, an imaging diagnosis will not only include the
location and extent of diseased lesions but also information on
the physiological characteristics and biological behaviour of the
lesion (e.g., perfusion, flow, metabolism, diffusion).
Molecular imaging is likely to replace several aspects of
ex vivo tissue analysis, which will be a key component in PM.
It is expected that molecular imaging can be used to detect
diseases much earlier because molecular and cellular changes
precede anatomical and structural changes on classical imag-
ing modalities such as CTandMRI. As such, it will contribute
to PM by treating the patient at the right time. As new thera-
pies will be increasingly based on a foundation of precise
understanding of the molecular basis of disease, simultaneous
creative probe development will require a deeper understand-
ing of cancer biology [50].
& Hypoxia is common in malignant tumours and increases the
resistance to radiation therapy. [18F]-fluoromixonidazole
([18F]-MISO) imaging enables the non-invasive assessment
of tumour hypoxia, and its use to predict response and sur-
vival benefits from treatment has been demonstrated in oe-
sophageal cancer, lung cancer and renal cell carcinoma
[51–53].
& Molecular imaging may help improve staging of malig-
nancies. In a preclinical animal model, detection of pros-
tate cancer and metastasis was possible with the use of an
imaging reporter gene under the control of the promoter of
astrocyte elevated gene-1 (AEG-1), which is selectively
active only in malignant cells. Metastatic lesions were
identified through bioluminescence imaging and SPECT
with a higher sensitivity than [18F]FDG and [18F]-NaF
[54].
Biology-based tissue biopsy in interventional radiology
PM currently requires an in-depth analysis of the genetic ex-
pression and molecular and cellular biology of the individual
disease. This is based on a more refined evaluation of tissue
samples by assessment of molecular and genetic expression
patterns. For example, for malignant tumours it is has become
relevant to know which of the genetic alterations is function-
ally relevant for abnormal cell proliferation.
Recent studies have shown that malignant lesions demon-
strate intratumoral heterogeneity with regard to genetic alter-
ations and expression patterns, thus indicating the existence of
multiple subpopulations of cells. Furthermore, metastatic
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lesions may have genetic expression patterns that differ from
the expression pattern in the primary lesion or from each other,
and these lesions can therefore show a different behaviour and
response to treatment. For more effective targeted therapy, it is
therefore necessary to identify these mutations and confirm
them by individual tissue analysis of each subset.
The differences in genetic expression patterns are frequent-
ly reflected as differences in imaging appearance. Imaging can
thus further play a crucial role in guiding the sampling proce-
dure. For example:
& Contrast-enhanced US in liver tumours not only increases
the accuracy of biopsies by improving the visualisation of
poorly visible lesions but also helps target the biopsy to
the hypervascular areas of a given lesion [55].
& [18F]FDG or [11C]-methionine-PET can detect hypermet-
abolic areas in brain tumours and improve the diagnostic
yield of stereotactic brain biopsy [56].
& PET-directed, US-guided biopsies with a PET/US fusion
targeted biopsy system improve prostate cancer detection
[57].
Theranostics/companion diagnostics
One of the classical examples of PM is the determination of
the status of the human epidermal growth factor receptor 2
(HER2) expression in patients with breast cancer as a prereq-
uisite for treatment with trastuzumab (Herceptin, Genentech).
In some cancers, HER2 is over-expressed, causing cancer
cells to reproduce uncontrollably [58]. Trastuzumab is a
monoclonal antibody that interferes with the HER2 receptor
and inhibits the effects of overexpression of HER2. This ap-
proach targets one of the core deregulated cellular signalling
pathways in cancer, which is totally different from cytotoxic
chemotherapy. If the breast cancer does not overexpress
HER2, trastuzumab will have no beneficial effect. The cou-
pling of therapy with diagnostic information specific for the
intended target is called a theranostic system.
In the HER2-trastuzumab theranostic system, the diagnos-
tic test is a laboratory test on a tissue specimen in vitro, but
in vivo imaging can also provide diagnostic tests for
theranostic systems. The most common example is 123I/131I
for targeted radionuclide radiotherapy in differentiated thyroid
cancer. Targeted radionuclide therapy combines “the
favourable targeting properties of peptides and antibodies with
the effectiveness of radiation-induced cell death. A major ad-
vantage is the possibility to determine the selective accumu-
lation in the targeted tissue by molecular imaging studies
using structurally identical diagnostic compounds” [59, 60].
Theranostics relying on in vitro testing of small tumour
samples does not address the problem of tumour hetero-
geneity or the phenotypic dedifferentiation of tumour
metastases. By using different molecular imaging tracers,
we begin to appreciate the heterogeneity of metastatic dis-
ease within individual patients. Tumour heterogeneity can
often be seen even within the same lesion. Thus, in a
patient with metastases of differing biology, a single ther-
apy approach may result in a mixed tumour response. It is
not possible to biopsy each and every lesion, so molecular
imaging is essential to successfully tailor treatment to the
individual tumour biology. A theranostic concept that uses
molecular imaging will better address the complexity of
tumour biology and will therefore have the potential to
enable improved diagnosis, treatment, and monitoring of
treatment response all at once [50].
Theranostics provide a unique signature for improved stag-
ing of the tumour, for imaging of the biodistribution of the
target to predict the biodistribution of the radiation dose and to
individually monitor the efficacy of treatment with the same
basic compound that is being used to target and treat the dis-
ease [60]. Furthermore, the development of new specific bio-
markers that can be used for both in-vivo diagnostic imaging
and targeted therapy with alpha emitter compounds or carriers
of cytotoxic agents will further expand the scope of the
application of theranostics in clinical practice. It is even
foreseeable that advanced targeted therapy, which is of-
ten extremely expensive, would only be applicable if we
have a companion diagnostic biomarker that can predict
the efficacy of the treatment.
Aside from the targeted therapy with 131I, other examples
of image-based theranostics are:
& The norepinephrine analogue metaiodobenzylguanidine
(MIBG) conjugated to 131I. MIBG is used for diagnostic
purposes, and it is available for targeted therapy of neuro-
endocrine tumours in adults and neuroblastoma in paedi-
atric patients [61, 62].
& Somatostatin peptide analogues are used in both imaging
and radionuclide-based therapy for endocrine tumours [63].
& Numerous other examples of paired molecular imaging
therapy are found with other radiopharmaceuticals that
are selective for biochemical processes, such as cellular
proliferation, steroid synthesis, growth factor receptor
expression, catecholamine production, hypoxia-induced
gene expression or apoptosis [64–66].
Nanotechnology
The evolving era of nanotechnology will further boost the devel-
opment and use of theranostics. Nanoparticle-based imaging and
therapeutic agents are a specific, advanced and promising form
of theranostics. Nanoparticles are synthesised from organic or
inorganic materials such as lipids, polymers, metals or semicon-
ductors. Thereafter ligands have to be conjugated to the
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nanoparticle in order to target cellular receptors (e.g.
overexpressed in tumour-induced angiogenesis) or other molec-
ular characteristics of diseased tissue [64]. In addition, visualisa-
tion is achieved by conjugation of imaging agents such as radio-
nuclides or paramagnetic/superparamagnetic metals. If the diag-
nostic scan demonstrates that the lesion is positive for the target,
the patient can be treated with the same nanoparticle, which now
carries the therapeutic agent. The therapeutic agent can be cyto-
toxic radionuclides or drugs encapsulated in the nanoparticle
structure. In the former case, the nanoparticles have to be
engineered with a moiety for chelation of radiometals. Other
materials that can be delivered locally are interfering RNAs,
genes and peptides. A major advantage of nanoparticles for
theranostics would be the high payload of both the therapeutic
agent and imaging probe that can be delivered to the target tissue.
Specific examples of theranostic agents currently under investi-
gation include:
& liposomal vesicle formulations containing cytostatic drugs
and MR contrast agents [67, 68].
& carbon nanotubes as multifunctional carriers for radioiso-
topes for treatment and imaging [69].
Radiogenomics/integrated diagnostics
Radiogenomics is a new approach in which large sets of com-
plex descriptors of disease are extracted from routine clinical
images and related to molecular biology and gene expression
patterns of disease [70, 71]. It is based on the assumption that
the observed image is the product of mechanisms occurring at
a genetic and molecular level. Thus, parameters extracted
through image processing and analysis are linked to the geno-
typic and phenotypic characteristics of the tissue [72].
Like other ‘omics techniques, it is not hypothesis-oriented
but goal-oriented. In radiogenomics, an a priori hypothesis is
not formulated on which imaging technique or feature should
be used to reflect a certain biological mechanism. Every imag-
inable feature is extracted from an image data set, including
semantic descriptors (e.g., shape, spiculated patterns, presence
of necrosis, localisation) and/or quantitative features. These
features are then correlated to gene expression profiles.
Radiogenomics is the term used when imaging features are
correlated to gene expression. The very large numbers of cor-
related parameters (usually over a hundred, ideally several
hundreds) extracted from the same data sets requires specific
statistical methods similar to those used in other ‘omics.
One of the first radiogenomics publications linked CT imag-
ing features to gene expression in hepatocellular carcinoma
[73]. The expression variation of over 6,000 genes was grouped
into 116 gene modules. By combining 28 imaging traits into
similar modules, 78 % of gene expression profiles could be
predicted. This means that the relative expression of a given
gene could be determined in any given liver tumour. This ap-
proach has been successfully applied to MRI features of glio-
blastoma multiforme and gene expression profiles, protein ex-
pression [74, 75], microRNAs [75], messenger RNA expres-
sion and DNA copy number variation [76]; to MRI features of
breast cancer and gene expression profiles [77]; to CT features
of renal cell carcinoma and gene mutations [78] and to
[18F]FDG features of lung cancer and protein expression [79].
It is clear that medical images inherently contain a wealth of
mineable information, which reflects genetic and molecular
information of disease in an individual patient. This would
potentially allow particular imaging phenotypes to serve as
surrogates for the unique molecular programmes that typify a
molecular subtype of cancer [80]. Radiogenomics will definite-
ly contribute to personalisation of patient management and help
improve existing staging and diagnostic schemes. Imaging can
be used to determine the molecular diversity of disease and
thereby stratify patients into molecular subclasses with different
prognoses [72]. For example, one study demonstrated that im-
aging features of hepatocellular carcinoma were predictive of a
gene expression profile of venous invasion genes and subse-
quently predictive of a poor outcome [73]. Equally important is
the use of imaging to identify patients for whom targeted ther-
apeutic agents will be effective. For example, one study dem-
onstrated that specific imaging traits in GBM were associated
with an EGFR protein expression programme and EGFR pro-
tein expression [74]. Finally, intratumoral genetic heterogeneity
can be reflected in intratumoral imaging heterogeneity, which
demonstrates one advantage of imaging over tissue analysis.
Although PM has been boosted by the huge developments
in molecular profiling, it is clear that nowadays imaging can
provide comparable information. However, competition be-
tween the two approaches is not foreseen as each acts on a
different level. Michael Kuo, one of the pioneers in
radiogenomics, sees a blurring of the traditional lines between
the diagnostic sciences and a merging of molecular diagnostics
and imaging into a single diagnostic discipline [80]. Integrated
diagnostics must include multimodality and multiparametric
imaging approaches as well as multiple pathologic, molecular
and genetic assays. This integration of the huge diagnostic data
from all levels—from genes, molecules, cells, tissues, organs
and organ systems—is needed in the era of PM.
Evaluation of treatment response
Imaging plays an important role in the assessment of thera-
peutic response. Classically decreased morbidity, e.g. relief of
symptoms, and mortality have been endpoints for treatment
evaluation. In most diseases treatment response can be evalu-
ated more objectively, reproducibly and earlier with imaging
than by monitoring symptoms. An early and accurate thera-
peutic response evaluation is critical in PM as it can influence
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the decision on discontinuation of treatment, treatment adjust-
ment and/or additional treatment. Imaging can spare patients
from prolonged exposure to ineffective treatments and allow
alternative therapies to be applied sooner. Imaging not only
plays a role in assessing response to chemotherapy, radiother-
apy and/or targeted therapies, but also in the monitoring of
changes after image-guided intervention.
Timing of response evaluation can differ according to clin-
ical needs. To prevent aggressive treatment—which could be
accompanied by severe side effects or expensive treatment in
non-responders — it is crucial to evaluate early response in
order to discontinue treatment and consider a second-line
treatment that is potentially more effective. However, final
treatment response evaluation is needed to decide on subse-
quent surgical treatment or neo-adjuvant treatment after
presurgical chemoradiotherapy.
Crucial in the evaluation of treatment is the assumption that
early tumour response is related to the final treatment response
and that both early and final treatment responses are related to
overall survival and/or progression-free survival. Multiple stud-
ies have already been performed that demonstrated these rela-
tionships. It is now time to integrate and translate these findings
into clinical trial design and clinical guidelines, which describe
the clinical decisions based on the results of imaging tests. This
is especially the case with the further expansion of cancer man-
agement based on PET imaging. For example:
& In colorectal cancer, PETof the liver could predict tumour
response to chemotherapy in liver metastasis, and PET of
the pelvis during or after (chemo)radiotherapy could pre-
dict the final tumour response and overall survival [46].
& Patients with advanced oesophageal cancer and no
evidence of response to neo-adjuvant chemoradio-
therapy on PET imaging, which occurs in 50 % of
the patients, have a worse prognosis after surgical
resection than patients who respond, even after rad-
ical surgical resection [81].
& For both limited stage and advanced stage Hodgkin lym-
phoma, multiple studies have demonstrated that interim
PET imaging has a high negative predictive value and a
moderate positive predictive value for progression-free
survival. Multiple trials are evaluating the effect of treat-
ment adaption based on early PET evaluation on
progression-free survival. These studies will determine
whether therapy can be safely escalated or reduced based
on treatment response evaluation [31].
How to assess treatment response?
Treatment monitoring in malignant tumours is based mainly
on anatomical imaging, frequently still assessed on 2D
images, e.g., according to the RECIST criteria. These
criteria have been expanded (RECIST 1.1) to include
lymph node evaluation and the use of PET [82]. Ana-
tomical imaging detects morphologic changes, which
occur relatively late during treatment. Over the last
decade, some shortcomings of anatomical imaging with
regards to therapy response have become evident [83].
These relate to a poor reproducibility of tumour mea-
surements [84, 85] and inconsistencies between tumour
response and survival [86]. Anatomical imaging alone
does not support a comprehensive understanding of tu-
mour biology. Furthermore, anatomical imaging falls
short of fully assessing the response to targeted thera-
pies that exert a cytostatic rather than a cytotoxic effect
as well as the early response assessment to neoadjuvant
systemic treatments.
The field of treatment response evaluation is a prime ex-
ample of the gap between current practice and advances in
imaging and image analysis techniques. Three-dimensional
display of lesions and volumetric measurements have ad-
vanced and may yield advantages in the assessment of tumour
response. For example, comparison of both single-diameter
and volumetric measurements to assess treatment response
demonstrated significant differences in tumour response [87,
88]. In addition, volumetric measurements for response as-
sessment provide more reproducible results [89]. Advances
in quantitative imaging and image analysis will contribute to
changing the landscape of clinical practice and clinical trials
[90, 91].
The development of new imaging techniques such as
molecular, metabolic and functional imaging has paralleled
the expanding knowledge on tumour biology. These tech-
niques provide additional critical information for care of
individual patients when used as a supplement to anatomic
imaging, as they expand the ability to biologically charac-
terise tumours and monitor tumour response at a more ap-
propriate level. Cancer is currently seen as a dysregulation
of a restricted number of signalling pathways, and treat-
ments that target these pathways will lead to successful
therapies. Molecular imaging helps assess changes in the
tumour that would indicate the activity of one or more of
the key dysregulated pathways. For example, for quantita-
tive analysis of tumour response, [18F]FDG-PET imaging
— which assesses the glucose uptake and thus the meta-
bolic activity level of various cancers — has been identi-
fied as a reliable indicator of treatment response. PET-based
scoring criteria extend the morphological RECIST criteria
into a biological dimension with a proposed PERSIST
score [92]. This approach was found to be more consistent
and showed better prediction of patient response to the
treatment in a variety of cancers. A wide range of more
specific probes and new imaging biomarkers are currently
emerging for assessment of individual types of cancer and
monitoring response to treatment.
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Advanced imaging can also target the problems related
to the use of one single marker for treatment response
evaluation. While intratumoral heterogeneity explains the
individual response to (targeted) therapy, a monitoring ap-
proach based on a single marker is not sensitive to non-
response in a heterogeneous lesion or in one of multiple
lesions. “This defines the weakness of serum analyses,
which provide an average signal of output from all le-
sions, or of a biopsy program to characterize a tumour—
if all can be different, then all must be characterized” [93].
Accurate localisation of regional differences in tumour be-
haviour and tissue characteristics is the strength of imag-
ing. But even a molecular imaging approach based on a
single probe may be insufficient, as alternative dysregulat-
ed signal pathways may replace the function of the
targeted pathway [93, 94]. Currently, imaging can be per-
formed with different modalities integrated into hybrid sys-
tems (SPECT/CT, PET/CT or PET/MRI) and can cover
several functional levels. Multi-parametric imaging can po-
tentially better identify heterogeneous and localised re-
sponse to treatment. By combining imaging markers from
different pathways, it may be possible to assess the type
of physiological escape mechanisms of a tumour (or other
disease) [94, 95], enabling individual treatment to be fitted
in real time to the type of response which is, of course,
PM in its most basic sense.
& For example, [15O]-labelled water PET to assess blood
perfusion and [18F]FDG-PET to assess glucose metabo-
lism was simultaneously applied in females with locally
advanced breast cancer treated with neoadjuvant chemo-
therapy. Changes in PET measures of tumour blood flow
and glucose metabolism predicted disease-free survival
and overall survival [96].
& Similar evaluation criteria could be expected by combin-
ing functional parameters of diffusion and perfusion im-
ages combined with metabolic PET data obtained using
hybrid PET/MR systems.
Imaging in drug discovery and drug trials
Treatment response is relevant for clinical practice but equally
important for pharmacological research, where it can be used
to identify and evaluate novel drugs. Indeed, in its Critical
Path Initiative, the US Food and Drug Administration
(FDA) has recognised the new role of medical imaging in drug
development and regulatory approval [97]. Although the Ini-
tiative emphasises the role of imaging in the assessment of
biomarkers, medical imaging also has other applications in
drug discovery: “a molecular imaging probe can be used to
determine target occupancy before and after administration of
a new drug candidate, which helps to assess binding affinity
and to determine correct dosages” [98].
In pharmaceutical research, the demonstration of tu-
mour response is an important element of early drug
development. Further investigation is often not per-
formed when antitumour activity and treatment response
are not demonstrated. Anatomical imaging is limited to
revealing a physical shrinkage of the tumour. With the
current molecular and functional imaging techniques all
kinds of antitumour activity can be detected such as
changes in receptor expression and tumour perfusion.
It is expected that these new techniques, which integrate
knowledge on the tumour biology, will foster the detec-
tion of relevant targeted drugs.
Very important is the increasing use of (imaging)
biomarkers as surrogate endpoints for clinical trials.
Given that validated surrogate endpoints allow dramatic
shortening of clinical trials by shortening the time to the
study end point, with associated savings and a faster
availability of new treatments, this is an area in which
both the pharmaceutical industry and healthcare author-
ities are pushing for biomarker use. Molecular imaging
and radiopharmaceuticals are particularly important
within this context as they allow in vivo visualisation
of the effect of the treatment.
Personalised treatment
Each intervention on a patient has a personalised approach.
This is true for surgery, radiotherapy and interventional radi-
ology. The same disease is treated differently based on disease
and patient characteristics provided by imaging before and
during the intervention. Imaging helps to plan and guide sur-
gical or minimally invasive individualised therapies. For ex-
ample, mapping of the anatomy before and during liver sur-
gery is based on imaging. Stereotactic brain biopsy is guided
by imaging. Surgical planning of brain tumours is based on
fMRI, which maps eloquent areas, and DTI, which visualises
relevant brain tracts [99]. In case of complications during an
intervention, the solution is even more individualised.
Radiotherapy
Imaging has always been involved in radiotherapy through
image-guided radiation therapy planning (RTP), including
the verification of treatment delivery. Delineation of pri-
mary and metastatic lesions, which helps to optimise target
volume definition in radiotherapy, is based on imaging.
Initially, the introduction of cross-sectional imaging has
tremendously improved the field of radiation oncology
[100]. Intensity-modulated radiotherapy, which improves
dose delivery to the tumour while reducing exposure of
healthy tissue to limit the side effects of treatment, re-
quires a precise delineation of the tumour. For that reason
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MRI is increasingly used in treatment planning as it pro-
vides better soft tissue contrast, which improves target
volume definition. A next step is the application of func-
tional imaging techniques, which can provide information
on more aggressive parts or more radiation-resistant parts
of the tumour. The target volume definition is then based
on the biology of the tumour.
& Hypoxia imaging with [18F]MISO-PET in head and neck
cancer can detect regions that are resistant to treatment.
Combined [18F]MISO-PET imaging and IMRT planning
permit dose painting with delivery of much higher doses
to hypoxic regions [101].
Some tumours are located in areas of the body that are
prone to movement, such as the lungs, liver and prostate
gland, and some tumours are located close to critical organs
and tissues. In these patients, image-guided radiation therapy
(IGRT) is used in which imaging immediately before or even
during a course of radiation therapy is applied to improve the
precision and accuracy of the delivery of treatment. In addi-
tion, another application of IGRT is the reduction of the target
volume during the course of radiation treatment based on the
visualisation of tumour shrinkage with imaging.
Interventional Radiology
Image-guided interventions provide the means to deliver ther-
apies locally at the disease site, whether the therapies are
based on chemical compounds (including drugs and
radiotherapeutics), genes, devices (including stents), cells,
sound waves (high-intensity focused ultrasound = HIFU) or
induction of ablative temperatures (using hyper- and hypo-
thermia with radiofrequency, microwaves or cryotherapy).
Most current interventional image-guided procedures are in-
dividually tailored to the local anatomic and functional cir-
cumstances as well as the personal needs of the patient. In this
way, image-guided interventions are in themselves an impor-
tant and integral part of PM. For example:
& Embolisation of bronchial arteries in patients with
haemoptysis is guided by CT angiography and DSA dur-
ing interventions.
& Decisions about the treatment of HCC depend on the lo-
cation, size and number of tumours at each time of pre-
sentation, favouring ablation for limited disease and
(chemo)embolic techniques for more extensive spread.
Medical imaging is going to play an important role in
individualised drug delivery. In the past 30 years, drug deli-
very research was focussed on targeting carriers such as lipo-
somes, polymeric nanoparticles and micelles to the disease
site. New developments now promote the selective release
of bioactive compounds after application of a trigger [102].
The trigger mechanism can be applied locally and at specific
times, depending on the individual patient’s needs, and can be
selectively applied with interventional techniques such as
HIFU under the guidance of MRI [102]. Although for many
reasons most tumour ablations are performed using percuta-
neous radiofrequency or microwaves, HIFU is the only clini-
cally viable technology that can be used to achieve a local
temperature increase deep inside the human body in a non-
invasive way. MRI can be used to provide continuous temper-
ature mapping duringHIFU for spatial and temporal control of
the heating procedure and prediction of the final lesion based
on the received thermal dose [103].
Conclusions and recommendations
The future of medicine is in early diagnosis and individually
tailored treatments, a concept that has been designated as
‘personalised medicine’ (PM), which relates to delivering the
right treatment to the right patient at the right time. For PM to
reach its full potential, medical imaging must be an integral part.
Imaging procedures are tailored to the clinical problem and
patient characteristics. Screening for preclinical disease is done
with imaging. Stratification based on imaging biomarkers can
help identify individuals suited for preventive intervention.
Treatment decisions are based on the in vivo visualisation of
the location and extent of an abnormality as well as the loco-
regional physiological, biochemical and biological processes
using structural and molecular imaging. Image-guided biopsy
provides relevant tissue specimens for genetic/molecular charac-
terisation. In addition, radiogenomics relate imaging biomarkers
to these genetic and molecular features. Furthermore, imaging is
essential to patient-tailored therapy planning, therapymonitoring
and follow-up of disease, as well as targeting non-invasive or
minimally invasive treatments, especially with the rise of
theranostics. Radiologists need to be prepared for this new par-
adigm as it will mean changes in training, clinical practice and
research.
In order for radiologists to take on these new challenges
they must be involved in the following activities:
& Promotion of the use of non-invasive medical imaging as
part of PM.
& Integration of anatomical, functional and molecular
imaging in one imaging department.
& Validation of quantitative imaging biomarkers for diagno-
sis and treatment repsonse assessment.
& Implementation of image-guided interventional proce-
dures for providing the most accurate tissue samples for
pathology-based biomarkers.
& Integration of personalised diagnostic imaging and thera-
peutic procedures (theranostics).
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& Provision of personalised image-based phenotypic results
that complement genomic analysis (radiogenomics).
& Esthablishment of large imaging biobanks that are linked
to other -omics data.
& Delivering personalised treatment via a wide range of in-
terventional radiologic procedures.
Acknowledgments This article was kindly prepared by the ESRWork-
ing Group on Personalised Medicine (Chair and lead/corresponding au-
thor: Aad van der Lugt; members: Thomas Beyer, Laure Fournier, S.
Nahum Goldberg, Hans-Ulrich Kauczor, Joachim Lotz, Riccardo
Manfredi, Osman Ratib, Pablo Rodriguez-Carnero, Siegfried Trattnig)
on behalf of the European Society of Radiology (ESR). It was approved
by the ESR Executive Council on 29 January 2015.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. European Society of Radiology (2011) Medical imaging in
personalised medicine: a white paper of the research commit-
tee of the European Society of Radiology (ESR). Insights
Imaging 2:621–630
2. European Commission (2014) Personalising health and care. https://
ec.europa.eu/research/participants/portal/desktop/en/opportunities/
h2020/topics/2282-phc-24-2015.html. Accessed 29 Dec 2014
3. European Science Foundation (2011) Personalised medicine for the
European citizen - towards more precise medicine for the diagnosis,
treatment and prevention of disease. http://www.esf.org/fileadmin/
Public_documents/Publications/Personalised_Medicine.pdf.
Accessed 29 Dec 2014
4. 4 National Academy of Sciences (2011) Toward Precision
Medicine: Building a Knowledge Network for Biomedical
Research and a New Taxonomy of Disease. http://dels.nas.edu/
Report/Toward-Precision-Medicine-Building-Knowledge/13284.
Accessed 29 Dec 2014
5. Siegel CA, Melmed GY (2009) Predicting response to Anti-TNF
Agents for the treatment of crohn’s disease. Therap Adv
Gastroenterol 2:245–251
6. The Royal College of Radiologists (2014) iRefer, making the best
use of clinical radiology. http://www.irefer.org.uk/. Accessed 29
Dec 2014
7. ACRAmerican College of Radiology (2014) ACRAppropriateness
Criteria http://www.acr.org/Quality-Safety/Appropriateness-
Criteria. Accessed 29 Dec 2014
8. Sung MK, Singh S, Kalra MK (2011) Current status of low dose
multi-detector CT in the urinary tract. World J Radiol 3:256–265
9. Kondo H, KanematsuM, Goshima S et al (2010) Body size indexes
for optimizing iodine dose for aortic and hepatic enhancement at
multidetector CT: comparison of total body weight, lean body
weight, and blood volume. Radiology 254:163–169
10. Liu J, Gao J, Wu R, Zhang Y, Hu L, Hou P (2013) Optimizing
contrast medium injection protocol individually with body weight
for high-pitch prospective ECG-triggering coronary CT angiogra-
phy. Int J Cardiovasc Imaging 29:1115–1120
11. ESR Eurosafe Imaging (2014) Eurosafe Imaging, Together for pa-
tient safety. http://www.eurosafeimaging.org/. Accessed 29 Dec
2014
12. Martin L, Ruddlesden R, Makepeace C, Robinson L, Mistry T,
Starritt H (2013) Paediatric x-ray radiation dose reduction and im-
age quality analysis. J Radiol Prot 33:621–633
13. European Society of Urogenital Radiology (2014) ESUR guide-
lines. http://www.esur.org/esur-guidelines/. Accessed 29 Dec 2014
14. May MS, Deak P, Kuettner A et al (2012) Radiation dose consider-
ations by intra-individual Monte Carlo simulations in dual source
spiral coronary computed tomography angiography with
electrocardiogram-triggered tube current modulation and adaptive
pitch. Eur Radiol 22:569–578
15. Frellesen C, Stock W, Kerl JM et al (2014) Topogram-based auto-
mated selection of the tube potential and current in thoraco-
abdominal trauma CT—a comparison to fixed kV with mAs mod-
ulation alone. Eur Radiol 24:1725–1734
16. Independent UKPoBCS (2012) The benefits and harms of breast
cancer screening: an independent review. Lancet 380:1778–1786
17. Levine MS, Yee J (2014) History, evolution, and current status of
radiologic imaging tests for colorectal cancer screening. Radiology
273:S160–S180
18. van Iersel CA, de Koning HJ, Draisma G et al (2007) Risk-based
selection from the general population in a screening trial: selection
criteria, recruitment and power for the Dutch-Belgian randomised
lung cancer multi-slice CT screening trial (NELSON). Int J Cancer
120:868–874
19. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl
Cancer Inst 102:605–613
20. van Klaveren RJ, Oudkerk M, Prokop M et al (2009) Management
of lung nodules detected by volume CT scanning. N Engl J Med
361:2221–2229
21. Evangelista L, Panunzio A, Polverosi R, Pomerri F, Rubello D
(2014) Indeterminate lung nodules in cancer patients: pretest prob-
ability of malignancy and the role of F-18-FDG PET/CT. American
Journal of Roentgenology 202:507–514
22. Kavousi M, Elias-Smale S, Rutten JH et al (2012) Evaluation of
newer risk markers for coronary heart disease risk classification: a
cohort study. Ann Intern Med 156:438–444
23. Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse
wave velocity improves cardiovascular event prediction: an individ-
ual participant meta-analysis of prospective observational data from
17,635 subjects. J Am Coll Cardiol 63:636–646
24. Saam T, Hetterich H, Hoffmann V et al (2013) Meta-analysis and
systematic review of the predictive value of carotid plaque hemor-
rhage on cerebrovascular events by magnetic resonance imaging. J
Am Coll Cardiol 62:1081–1091
25. Arias F, Chicata V, Garcia-Velloso MJ et al (2014) Impact of initial
FDG PET/CT in the management plan of patients with locally ad-
vanced head and neck cancer. Clin Transl Oncol. doi:10.1007/
s12094-014-1204-8
26. Forner A, Bruix J (2013) The size of the problem: clinical algo-
rithms. Dig Dis 31:95–103
27. De Leyn P, Dooms C, Kuzdzal J et al (2014) Revised ESTS guide-
lines for preoperative mediastinal lymph node staging for non-
small-cell lung cancer. Eur J Cardiothorac Surg 45:787–798
28. Silvestri GA, Gonzalez AV, Jantz MA et al (2013) Methods for
staging non-small cell lung cancer: Diagnosis and management of
lung cancer, 3rd ed: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest 143:e211S–250S
29. European Society for Medical Oncology ESMO Clinical Practice
Guidelines. http://www.esmo.org/Guidelines. Accessed 29 Dec
2014
30. Czernin J, Allen-Auerbach M, Schelbert HR (2007) Improvements
in cancer staging with PET/CT: literature-based evidence as of
September 2006. J Nucl Med 48(Suppl 1):78S–88S
31. Kostakoglu L, Cheson BD (2014) Current role of FDG PET/CT in
lymphoma. Eur J Nucl Med Mol Imaging 41:1004–1027
Insights Imaging (2015) 6:141–155 153
32. van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of
positron emission tomography in the preoperative assessment of
patients with suspected non-small-cell lung cancer: the PLUS
multicentre randomised trial. Lancet 359:1388–1393
33. Steiner T, Juvela S, Unterberg A et al (2013) European Stroke
Organization guidelines for the management of intracranial aneu-
rysms and subarachnoid haemorrhage. Cerebrovasc Dis 35:93–112
34. Moll FL, Powell JT, Fraedrich G et al (2011) Management of ab-
dominal aortic aneurysms clinical practice guidelines of the
European society for vascular surgery. Eur J Vasc Endovasc Surg
41(Suppl 1):S1–S58
35. Rothwell PM, Gutnikov SA,Warlow CP, European Carotid Surgery
Trialist’s C (2003) Reanalysis of the final results of the European
Carotid Surgery Trial. Stroke 34:514–523
36. Mowatt G, Scotland G, Boachie C et al (2013) The diagnostic ac-
curacy and cost-effectiveness of magnetic resonance spectroscopy
and enhanced magnetic resonance imaging techniques in aiding the
localisation of prostate abnormalities for biopsy: a systematic re-
view and economic evaluation. Health Technol Assess 17:1–281
37. Cornelis F, Rigou G, Le Bras Y et al (2013) Real-time contrast-
enhanced transrectal US-guided prostate biopsy: diagnostic accura-
cy in men with previously negative biopsy results and positive MR
imaging findings. Radiology 269:159–166
38. Mahoney MC, Newell MS (2013) Breast intervention: how I do it.
Radiology 268:12–24
39. Balu-Maestro C, Ianessi A, Chapellier C, Marcotte C, Stolear S
(2013) Ultrasound-guided lymph node sampling in the initial man-
agement of breast cancer. Diagn Interv Imaging 94:389–394
40. Monfardini L, Preda L, Aurilio G et al (2014) CT-guided bone
biopsy in cancer patients with suspected bonemetastases: retrospec-
tive review of 308 procedures. Radiol Med 119:852–860
41. van den Brekel MW, Castelijns JA (2005) What the clinician wants
to know: surgical perspective and ultrasound for lymph node imag-
ing of the neck. Cancer Imaging 5(Spec No A):S41–49
42. Nakajima N, Kataoka M, Sugawara Y et al (2013) Volume-based
parameters of 18F-fluorodeoxyglucose positron emission
tomography/computed tomography improve disease recurrence pre-
diction in postmastectomy breast cancer patients with 1 to 3 positive
axillary lymph nodes. Int J Radiat Oncol Biol Phys 87:738–746
43. Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL,
Mahmood U (2013) Baseline total lesion glycolysis measured with
(18)F-FDG PET/CT as a predictor of progression-free survival in
diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol
Imaging 3:272–281
44. Fournier LS, Oudard S, Thiam R et al (2010) Metastatic renal car-
cinoma: evaluation of antiangiogenic therapy with dynamic
contrast-enhanced CT. Radiology 256:511–518
45. Mannelli L, Patterson AJ, Zahra M et al (2010) Evaluation of
nonenhancing tumor fraction assessed by dynamic contrast-
enhanced MRI subtraction as a predictor of decrease in tumor vol-
ume in response to chemoradiotherapy in advanced cervical cancer.
AJR Am J Roentgenol 195:524–527
46. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT,
Oyen WJ (2009) Monitoring and predicting response to therapy
with 18F-FDG PET in colorectal cancer: a systematic review. J
Nucl Med 50(Suppl 1):43S–54S
47. Kyriazi S, Collins DJ,Messiou C et al (2011)Metastatic ovarian and
primary peritoneal cancer: assessing chemotherapy response with
diffusion-weighted MR imaging–value of histogram analysis of ap-
parent diffusion coefficients. Radiology 261:182–192
48. Berger M (2006) Molecular imaging as a step towards personalized
medicine. http://www.nanowerk.com/spotlight/spotid=1001.php.
Accessed 29 Dec 2014
49. European Science Foundation (2007) Science policy Briefing 28,
Medical Imaging for Improved Patient Care. http://www.esf.org/
fileadmin/links/EMRC/ESF_POLICY28_V09_HD.pdf. Accessed
29 Dec 2014
50. HricakH (2011) Oncologic imaging: a guiding hand of personalized
cancer care. Radiology 259:633–640
51. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M (2006)
Combined uptake of [18F]FDG and [18F]FMISO correlates with
radiation therapy outcome in head-and-neck cancer patients.
Radiother Oncol 80:151–156
52. Hugonnet F, Fournier L, Medioni J et al (2011) Metastatic renal cell
carcinoma: relationship between initial metastasis hypoxia, change
after 1 month’s sunitinib, and therapeutic response: an 18 F-
fluoromisonidazole PET/CT study. J Nucl Med 52:1048–1055
53. Eschmann SM, Paulsen F, Reimold M et al (2005) Prognostic im-
pact of hypoxia imaging with 18 F-misonidazole PET in non-small
cell lung cancer and head and neck cancer before radiotherapy. J
Nucl Med 46:253–260
54. Bhatnagar A, Wang Y, Mease RC et al (2014) AEG-1 promoter-
mediated imaging of prostate cancer. Cancer Res 74:5772–5781
55. Sparchez Z, Radu P, Zaharia T et al (2011) Usefulness of contrast
enhanced ultrasound guidance in percutaneous biopsies of liver tu-
mors. J Gastrointestin Liver Dis 20:191–196
56. Pirotte B, Goldman S, Salzberg S et al (2003) Combined positron
emission tomography and magnetic resonance imaging for the plan-
ning of stereotactic brain biopsies in children: experience in 9 cases.
Pediatr Neurosurg 38:146–155
57. Fei B, Nieh PT, Schuster DM, Master VA (2013) PET-directed, 3D
Ultrasound-guided prostate biopsy. Diagn Imaging Eur 29:12–15
58. Hudis CA (2007) Trastuzumab–mechanism of action and use in
clinical practice. N Engl J Med 357:39–51
59. Wangler C, Buchmann I, EisenhutM, Haberkorn U, MierW (2007)
Radiolabeled peptides and proteins in cancer therapy. Protein Pept
Lett 14:273–279
60. Bouchelouche K, Capala J (2010) ‘Image and treat’: an individual-
ized approach to urological tumors. Curr Opin Oncol 22:274–280
61. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen
HM, Caron HN (2008) Iodine-131-metaiodobenzylguanidine as ini-
tial induction therapy in stage 4 neuroblastoma patients over 1 year
of age. Eur J Cancer 44:551–556
62 . Po s t ema EJ , McEwan AJ ( 2009 ) Rad i o i od i n a t e d
metaiodobenzylguanidine treatment of neuroendocrine tumors in
adults. Cancer Biother Radiopharm 24:519–525
63. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R,
Kwekkeboom DJ (2009) Peptide-receptor radionuclide therapy for
endocrine tumors. Nat Rev Endocrinol 5:382–393
64. Lee DY, Li KC (2011) Molecular theranostics: a primer for the
imaging professional. AJR Am J Roentgenol 197:318–324
65. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA
(2008) Tumor receptor imaging. J Nucl Med 49(Suppl 2):149S–
163S
66. Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M (2007)
Nuclear imaging in cancer theranostics. Q J Nucl MedMol Imaging
51:152–163
67. Kim MJ, Jang DH, Lee YI, Jung HS, Lee HJ, Choa YH (2011)
Preparation, characterization, cytotoxicity and drug release behavior
of liposome-enveloped paclitaxel/Fe3O4 nanoparticles. J Nanosci
Nanotechnol 11:889–893
68. Kono K, Nakashima S, Kokuryo D et al (2011) Multi-functional
liposomes having temperature-triggered release and magnetic reso-
nance imaging for tumor-specific chemotherapy. Biomaterials 32:
1387–1395
69. Hong SY, Tobias G, Al-Jamal KT et al (2010) Filled and glycosyl-
ated carbon nanotubes for in vivo radioemitter localization and im-
aging. Nat Mater 9:485–490
70. Kuo MD, Jamshidi N (2014) Behind the numbers: Decoding mo-
lecular phenotypes with radiogenomics–guiding principles and
technical considerations. Radiology 270:320–325
154 Insights Imaging (2015) 6:141–155
71. Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tu-
mour phenotype by noninvasive imaging using a quantitative
radiomics approach. Nat Commun 5:4006
72. Rutman AM, Kuo MD (2009) Radiogenomics: creating a link be-
tween molecular diagnostics and diagnostic imaging. Eur J Radiol
70:232–241
73. Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene ex-
pression programs in liver cancer by noninvasive imaging. Nat
Biotechnol 25:675–680
74. Diehn M, Nardini C, Wang DS et al (2008) Identification of nonin-
vasive imaging surrogates for brain tumor gene-expression mod-
ules. Proc Natl Acad Sci U S A 105:5213–5218
75. Zinn PO, Mahajan B, Sathyan P et al (2011) Radiogenomic map-
ping of edema/cellular invasion MRI-phenotypes in glioblastoma
multiforme. PLoS One 6:e25451
76. Jamshidi N, Diehn M, Bredel M, Kuo MD (2014) Illuminating
radiogenomic characteristics of glioblastoma multiforme through
integration of MR imaging, messenger RNA expression, and
DNA copy number variation. Radiology 270:1–2
77. Yamamoto S, Maki DD, Korn RL, Kuo MD (2012) Radiogenomic
analysis of breast cancer using MRI: a preliminary study to define
the landscape. AJR Am J Roentgenol 199:654–663
78. Karlo CA, Di Paolo PL, Chaim J et al (2014) Radiogenomics of
clear cell renal cell carcinoma: associations between CT imaging
features and mutations. Radiology 270:464–471
79. Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R (2014) NF-
kappaB protein expression associates with (18)F-FDG PET tumor
uptake in non-small cell lung cancer: a radiogenomics validation
study to understand tumor metabolism. Lung Cancer 83:189–196
80. Kuo MD, Yamamoto S (2011) Next generation radiologic-
pathologic correlation in oncology: Rad-Path 2.0. AJR Am J
Roentgenol 197:990–997
81. Salavati A, Basu S, Heidari P, Alavi A (2009) Impact of
fluorodeoxyglucose PETon the management of esophageal cancer.
Nucl Med Commun 30:95–116
82. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response
evaluation criteria in solid tumours: revised RECIST guideline (ver-
sion 1.1). Eur J Cancer 45:228–247
83. Carnaghi C, Sclafani F, Basilico V, Doherty M (2011) Response
assessment in oncology: limitations of anatomic response criteria
in the era of tailored treatments. Q J Nucl Med Mol Imaging 55:
589–602
84. Ford R, Schwartz L, Dancey J et al (2009) Lessons learned from
independent central review. Eur J Cancer 45:268–274
85. Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver
and intraobserver variability in measurement of non-small-cell car-
cinoma lung lesions: implications for assessment of tumor response.
J Clin Oncol 21:2574–2582
86. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in ad-
vanced hepatocellular carcinoma. N Engl J Med 359:378–390
87. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE
(2002) CT tumor measurement for therapeutic response assessment:
comparison of unidimensional, bidimensional, and volumetric tech-
niques initial observations. Radiology 225:416–419
88. Shah GD, Kesari S, Xu R et al (2006) Comparison of linear and
volumetric criteria in assessing tumor response in adult high-grade
gliomas. Neuro Oncol 8:38–46
89. Frauenfelder T, Tutic M, Weder W et al (2011) Volumetry: an alter-
native to assess therapy response for malignant pleural mesothelio-
ma? Eur Respir J 38:162–168
90. Buckler AJ, Mozley PD, Schwartz L et al (2010) Volumetric CT in
lung cancer: an example for the qualification of imaging as a bio-
marker. Acad Radiol 17:107–115
91. Liu F, Zhao B, Krug LM et al (2010) Assessment of therapy re-
sponses and prediction of survival in malignant pleural mesothelio-
ma through computer-aided volumetric measurement on computed
tomography scans. J Thorac Oncol 5:879–884
92. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST
to PERCIST: Evolving Considerations for PET response criteria in
solid tumors. J Nucl Med 50(Suppl 1):122S–150S
93. Nunn AD (2007) Molecular imaging and personalized medicine: an
uncertain future. Cancer Biother Radiopharm 22:722–739
94. Eckelman WC, Reba RC, Kelloff GJ (2008) Targeted imaging: an
important biomarker for understanding disease progression in the
era of personalized medicine. Drug Discov Today 13:748–759
95. Padhani AR, Miles KA (2010) Multiparametric imaging of tumor
response to therapy. Radiology 256:348–364
96. Dunnwald LK, Gralow JR, Ellis GK et al (2008) Tumormetabolism
and blood flow changes by positron emission tomography: relation
to survival in patients treated with neoadjuvant chemotherapy for
locally advanced breast cancer. J Clin Oncol 26:4449–4457
97. U.S. Food and Drug Administration (2009) Medical Imaging and
D r u g D e v e l o pm e n t . h t t p : / / www. f d a . g o v / D r u g s /
DevelopmentApprovalProcess/DevelopmentResources/
ucm092895.htm. Accessed 29 Dec 2014
98. Thrall JH (2004) Personalized medicine. Radiology 231:613–616
99. Smits M, Vernooij MW, Wielopolski PA, Vincent AJ, Houston GC,
van der Lugt A (2007) Incorporating functional MR imaging into
diffusion tensor tractography in the preoperative assessment of the
corticospinal tract in patients with brain tumors. AJNR Am J
Neuroradiol 28:1354–1361
100. Dawson LA, Jaffray DA (2007) Advances in image-guided radia-
tion therapy. J Clin Oncol 25:938–946
101. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K,
Rajendran J (2011) Hypoxia imaging with [F-18] FMISO-PET in
head and neck cancer: potential for guiding intensity modulated
radiation therapy in overcoming hypoxia-induced treatment resis-
tance. Radiother Oncol 101:369–375
102. Crommelin DJ, Storm G, Luijten P (2011) ‘Personalised medicine’
through ‘personalised medicines’: time to integrate advanced, non-
invasive imaging approaches and smart drug delivery systems. Int J
Pharm 415:5–8
103. Moonen CT (2007) Spatio-temporal control of gene expression and
cancer treatment using magnetic resonance imaging-guided focused
ultrasound. Clin Cancer Res 13:3482–3489
104. Wikipedia (2014) Personalized medicine. http://en.wikipedia.org/
wiki/Personalized_medicine. Accessed 29 Dec 2014
105. National Institute of Health. National Human Genome Research
Institute (2015) Talking Glossary of Genetic Terms. Personalized
Medicine. http://www.genome.gov/glossary/index.cfm?id=150.
Accessed 29 Dec 2014
106. National Cancer Institute (2015) NCI Dictionary of Cancer Terms.
http://www.cancer.gov/dictionary?CdrID=561717. Accessed 29
Dec 2014
107. Xie J, Lee S, Chen X (2010) Nanoparticle-based theranostic agents.
Adv Drug Deliv Rev 62:1064–1079
108. U.S. Food and Drug Administration (2015) List of cleared or
approved companion diagnostic devices (In Vitro and
Imaging Tools). http:/ /www.fda.gov/MedicalDevices/
P roduc t sandMedica lProcedures / InVi t roDiagnos t i c s /
ucm301431.htm. Accessed 29 Dec 2014
Insights Imaging (2015) 6:141–155 155
